Hysterectomy

Patients Embrace Legislative Deal to Update Malpractice Cap, Forestall Ballot Fight on Fairness for Injured Patients Act in November says Consumer Watchdog

Retrieved on: 
Wednesday, April 27, 2022
Legislation, Disability, Family, Patient, Trauma, Income, Death, Color, Woman, Cedars-Sinai Medical Center, Injury, Catastrophic injury, News, Consumer Watchdog, Fairness, Severe cognitive impairment, Hysterectomy, Survivor, Grief, Skin, Health insurance, Life insurance

The families said the legislation would eliminate the need for the Fairness for Injured Patients Act to go before voters in November 2022.

Key Points: 
  • The families said the legislation would eliminate the need for the Fairness for Injured Patients Act to go before voters in November 2022.
  • ScottOlsen, a board member for Consumer Watchdog, became a proponent of the Fairness for Injured Patients Act after the cap reduced a $7 million verdict for his son's lifetime of blindness and disability to $250,000.
  • "If the legislaturefully enacts the meaningful reforms in this proposed comprise before June 29th, I will agree to withdraw the Fairness for Injured Patients Act from the ballot,"Olsensaid.
  • And doctors will be free to apologize to patients and even acknowledge mistakes without their apology being held against them in court.

Minerva Surgical to Announce First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, April 27, 2022
Uterus, Holocene, Nasdaq, GLOBE, Interest, Abnormal uterine bleeding, Company, Telephone, Woman, Hysterectomy, Minerva, AUB, Medical device

SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022.

Key Points: 
  • SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Recent Events section of the companys website at http://ir.minervasurgical.com .
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.

Minerva Surgical Announces AUB Awareness Day

Retrieved on: 
Tuesday, April 26, 2022
Obstetrics, ACOG, CEO, Awareness, Woman, Uterus, Minerva, AUB, Hysterectomy, GLOBE, Internal bleeding, Nasdaq, Company, Abnormal uterine bleeding, American College, Mother, Medical device, Birth control, Gynaecology

SANTA CLARA, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womens health company focused on the treatment of AUB (Abnormal Uterine Bleeding), today announced the debut of the first ever AUB Awareness Day on May 18, 2022.

Key Points: 
  • SANTA CLARA, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womens health company focused on the treatment of AUB (Abnormal Uterine Bleeding), today announced the debut of the first ever AUB Awareness Day on May 18, 2022.
  • AUB has a variety of causes and symptoms and can leave a woman feeling as if life revolves around her period.
  • Dave Clapper, President & CEO of Minerva Surgical, states, Our mission is to increase awareness of this common condition that affects 1 in 3 women and is the leading cause of hysterectomies.
  • Minerva is attending the American College of Obstetrics and Gynecology (ACOG) Annual Meeting in San Diego, CA from May 6-8, 2022, and invites attendees to visit Booth 1821 to meet our team, learn about AUB Awareness Day and the educational resources available to them.

Florasophy Weighs Fiber as Medicine

Retrieved on: 
Thursday, April 7, 2022
Eating, Carson, Metabolism, Barnett, Â, Digestion, CNS, PMS, Hysterectomy, Woman, Prescription, Pimley School, Daily, GLOBE, Vegetable, Water, Patient, Collection, Dietary supplement

Containing more than 4 grams of soluble fiber per serving, Florasophy supplements offer a concentrated, convenient source of daily fiber for adults and children alike.

Key Points: 
  • Containing more than 4 grams of soluble fiber per serving, Florasophy supplements offer a concentrated, convenient source of daily fiber for adults and children alike.
  • The result was Florasophy fiber blends, a powder supplement designed to mix with water, juice, or smoothies, and packaged in eco-friendly packaging, available nationwide.
  • For more information about Florasophy products and how you can improve your gut health through maximizing your soluble fiber intake, visit thinkflorasophy.com .
  • Florasophy is a collection of clinician-developed, soluble fiber blends that optimize digestion, enhance detoxification, and promote overall well-being.

Innocoll Announces Positive Topline Results For XARACOLL® (bupivacaine hydrochloride) implant in a Phase 3 Study to Support Expanded Use

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Risk, Shanda, Toxicity, Patient, Tremor, Hydrogen chloride, Industry, Anesthetic, Population, Abdominoplasty, Food, Seroma, Methemoglobinemia, Safety, GPC, Blurred vision, Bupivacaine, Colectomy, FDA, Program, Kerala State Drugs and Pharmaceuticals Limited, Headache, Hysterectomy, BMJ, Rash, DO, Hernia, Diffusion, Association, US Foods, Dysgeusia, Liver, Constipation, Publication, Incidence, Back pain, Blood pressure, Pharmaceutical industry, Dentistry, Birth control, Medical device, Fever

This data complements the positive results of XARACOLL in acute post-surgical pain following open inguinal hernia repair in adults, for which XARACOLL is currently approved.

Key Points: 
  • This data complements the positive results of XARACOLL in acute post-surgical pain following open inguinal hernia repair in adults, for which XARACOLL is currently approved.
  • These positive topline Phase 3 clinical trial results will support Innocolls soft tissue surgery development program and its anticipated sNDA application to expand the indications for XARACOLL.
  • We are excited to report the positive results of this Phase 3 clinical trial with XARACOLL.
  • XARACOLL implant releases bupivacaine after placement at the surgical site through diffusion from the porous collagen implant, which dissolves over time.

Minerva Surgical to Announce Fourth Quarter and Full-Year Financial Results

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Nasdaq, Holocene, Hysterectomy, Woman, Uterus, Abnormal uterine bleeding, Minerva, AUB, Telephone, Interest, Medical device

SANTA CLARA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full-year 2021 financial results on Tuesday, March 8, 2022.

Key Points: 
  • SANTA CLARA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full-year 2021 financial results on Tuesday, March 8, 2022.
  • In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Recent Events section of the companys website at http://ir.minervasurgical.com .
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.

Minerva Surgical to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Monday, January 31, 2022
Abnormal uterine bleeding, Hysterectomy, Uterus, Conference, AUB, Woman, GLOBE, Minerva, Nasdaq, Medical device

SANTA CLARA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 3:40 p.m. Eastern Time.

Key Points: 
  • SANTA CLARA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a womans health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that its management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 3:40 p.m. Eastern Time.
  • Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
  • The company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies.
  • The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.

Largest Study to Date on COVID19 Pregnancy Outcomes Published in American Journal of Obstetrics and Gynecology

Retrieved on: 
Friday, January 14, 2022
Medicine, Research, American Board of Commissioners for Foreign Missions, Gynaecology, Preterm birth, MERS, WWAMI Regional Medical Education Program, Coronaviridae, MIGS, COVID19, Travel, SARS, Workplace, Tucson Medical Center, American Board of Obstetrics and Gynecology, Obstetrics, American Journal of Obstetrics and Gynecology, Mother, Hysterectomy, Uterus, American Journal, Health, Interview, Pregnancy, Sexual Offences Act 1956, Society, Education, SLS, Lead author, Guinness World Records, Risk, OBGYN, Institute, Neonatology, Endocrinology, COVID, Dentistry, Pediatrics

MESA, Ariz., Jan. 14, 2022 PRNewswire/ -- Newly published today in the American Journal of Obstetrics and Gynecology is the largest study performed thus far on the effect of the COVID19 virus in pregnancy.

Key Points: 
  • MESA, Ariz., Jan. 14, 2022 PRNewswire/ -- Newly published today in the American Journal of Obstetrics and Gynecology is the largest study performed thus far on the effect of the COVID19 virus in pregnancy.
  • "In the largest study to date, a strong connection between COVID19 infection in pregnancy and preterm birth is seen."
  • Marchand holds dual certifications from the American Board of Obstetrics and Gynecology in both general OBGYN and Minimally Invasive Gynecologic Surgery.
  • About The American Journal of Obstetrics and Gynecology:AJOG Global Reports is one of two companion titles to the highly-respected American Journal of Obstetrics and Gynecology.

Minerva Surgical Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

Retrieved on: 
Tuesday, January 11, 2022
U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Forward-looking statement, SEC, COVID-19, Risk, Minerva, Hysterectomy, Uterus, GLOBE, Review, Time, Nasdaq, CIBC, Company, Projection, AUB, Securities Act of 1933, Omicron, Woman, Medical device, Audit

Preliminary Fourth Quarter and Full Year 2021 Highlights:

Key Points: 
  • Preliminary Fourth Quarter and Full Year 2021 Highlights:
    Fourth quarter 2021 revenues are expected to be in the range of $13.5M - $13.7M, compared with revenues of $13.6M in fourth quarter of 2020.
  • Ended 2021 with over $40M in cash and cash equivalents, reflecting the proceeds from the Companys initial public offering completed on October 26, 2021.
  • The fourth quarter of 2021 was a busy time for our team, and Im very pleased with our execution on a number of fronts.
  • Despite the continuing challenges from COVID-19, we are seeing good progress in establishing new commercial accounts, said David M. Clapper, Minerva Surgical Chief Executive Officer.

Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update

Retrieved on: 
Monday, January 10, 2022
Pharmaceutical, Surgery, Health, FDA, Medical Devices, Data Management, Technology, Other Health, Securities Act of 1933, SEC, Intelligence, Deep learning, Safety, Efficiency, Growth, 3D, TRUST, Digital, Security (finance), Securities Exchange Act of 1934, Urology, Goal, Investment, Hospital, General surgery, Hysterectomy, Image, Anatomy, Sale, U.S. Securities and Exchange Commission, Pain, Decision-making, ISU, Program, PGS, Gynaecology, CEO, NYSE, Time-invariant system, Company, Private Securities Litigation Reform Act, Health, Technology, Surgeon, CE marking, Movement, Surgery, FDA, Adoption, Dentistry, Video game, Medical device, Animal, Medical imaging, EMEA

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today provided a preliminary 2021 year-end corporate update.

Key Points: 
  • Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery, today provided a preliminary 2021 year-end corporate update.
  • Throughout 2021, the Company initiated 10 Senhance Surgical Program initiations: one in the US, six in EMEA, and three in Asia.
  • In 2021, surgeons performed over 2,000 procedures utilizing the Senhance System, representing a 42% increase over the previous year.
  • This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability.